Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid
- 1 October 1998
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 139 (4) , 655-659
- https://doi.org/10.1046/j.1365-2133.1998.02462.x
Abstract
This double-blind randomized study was designed to compare the efficacy and safety of calcipotriol ointment (50 μg/g) with betamethasone dipropionate (64 mg/g) and salicylic acid (0.03 g/g) ointment in the treatment of nail bed psoriasis. Fifty-eight patients applied the given drug to the affected nails twice a day for 3–5 months, depending on clinical response. Efficacy was assessed monthly on the basis of nail thickness, measured in millimetres. Photographs of the treated nails were taken at baseline, and after 3 and 5 months. Tolerability was assessed at 3 and 5 months. In patients with fingernail psoriasis, after 3 months of treatment subungual hyperkeratosis was reduced from 2.3 ± 0.1 mm (mean ± SEM) to 1.5 ± 0.1 mm (−26.5%) in the calcipotriol group and from 2.3 ± 0.1 mm to 1.6 ± 0.1 mm (−30.4%) in the betamethasone dipropionate and salicylic acid group [not significant (NS) between treatments, analysis of variance ( ANOVA)]. After 5 months, responders showed a 49.2% reduction in hyperkeratosis in the calcipotriol group (from 2.8 ± 0.1 mm to 1.4 ± 0.2 mm) and 51.7% (from 2.1 ± 0.1 mm to 1.0 ± 0.1 mm) in the betamethasone dipropionate and salicylic acid group (P < 0.001 from baseline, NS between treatments, ANOVA). In patients with toenail psoriasis, after 3 months of treatment there was an overall reduction in hyperkeratosis from 2.6 ± 0.1 mm to 2.1 ± 0.1 mm (−20.1%) in the calcipotriol group and from 3.0 ± 0.1 mm to 2.3 ± 0.1 mm (−22.9%) in the betamethasone dipropionate and salicylic acid group (P < 0.001 from baseline, NS between treatments, ANOVA). By the end of the fifth month there was a 40.7% reduction in hyperkeratosis in the calcipotriol group (from 2.1 ± 0.1 mm to 1.2 ± 0.1 mm) and 51.9% in the betamethasone dipropionate and salicylic acid group (from 2.7 ± 0.1 mm to 1.3 ± 0.1 mm; P < 0.0001 from baseline, NS between treatments, ANOVA). The results of the study show that calcipotriol is as effective as a combination of a topical steroid with salicylic acid in the treatment of nail psoriasis and represents a safe alternative in the topical treatment of nail psoriasis.Keywords
This publication has 9 references indexed in Scilit:
- A simplified protocol of steroid injection for psoriatic nail dystrophyBritish Journal of Dermatology, 1998
- Successful treatment for acrodermatitis continua of Hallopeau using topical calcipotriolBritish Journal of Dermatology, 1996
- A Text Atlas of Nail DisordersPublished by Taylor & Francis ,1996
- Acrodermatitis continua of Hallopeau: Response to Combined Treatment with Acitretin and Calcipotriol OintmentDermatology, 1996
- Nail psoriasis treated with calcipotriol (MC 903): an open studyJournal of Dermatological Treatment, 1994
- CalcipotriolDrugs, 1992
- Corticosteroid-induced ‘disappearing digit’Journal of the American Academy of Dermatology, 1990
- Acroatrophy secondary to long-standing applications of topical steroidsArchives of Dermatology, 1990
- Distal phalangeal atrophy secondary to topical steroid therapyArchives of Dermatology, 1987